TherapeuticsMD (NSDQ:TXMD) shares fell -7% yesterday after the company announced that the FDA accepted its resubmitted application for TX-004HR, an investigational, applicator-free estradiol vaginal soft-gel capsule for the treatment of dyspareunia.
The company’s shares took a hit presumably because it revealed that its resubmitted application is a Class 2 response – a Class 1 response would have quickened the timeline for potential approval. As a Class 2 response, the FDA is slated to make a decision in six months.
Get the full story at our sister site, Drug Delivery Business News.